Zeybek, Burak
Manzano, Aranzazu
Bianchi, Anna
Bonazzoli, Elena http://orcid.org/0000-0003-2024-8102
Bellone, Stefania
Buza, Natalia
Hui, Pei
Lopez, Salvatore http://orcid.org/0000-0001-7705-3715
Perrone, Emanuele
Manara, Paola
Zammataro, Luca
Altwerger, Gary
Han, Chanhee
Tymon-Rosario, Joan
Menderes, Gulden
Ratner, Elena
Silasi, Dan-Arin
Huang, Gloria S.
Azodi, Masoud
Schwartz, Peter E.
Santin, Alessandro
Funding for this research was provided by:
Foundation for the National Institutes of Health (CA-16359, U01 CA176067-01A1)
Deborah Bunn Alley Ovarian Cancer Research Foundation
Honorable Tina Brozman Foundation
Discovery To Cure
Fondazione Guido Berlucchi
Immunomedics
Article History
Received: 29 August 2019
Accepted: 9 January 2020
First Online: 22 January 2020
Competing interests
: Dr Santin’s work has been funded by U01 CA176067-01A1 grants from NIH, CA-16359 grant from the NCI and grants from Deborah Bunn Alley Foundation, Tina Brozman Foundation, Discovery to Cure Foundation, SU2C and Guido Berlucchi Foundation, and by Immunomedics, Inc. Dr Santin declares research funding support from Institution from Puma, Gilead, Immunomedics, Synthon, and Tesaro and non-financial support (ie, reagents) from Genentech/Roche, Merck, Boehringer Ingelheim, Genentech, Array BioPharma Inc, AstraZeneca, ImmunoGen. Dr Manzano declares that she receives research funding support from Spanish Medical Oncology Society. Dr Zeybek, Ms Bianchi, Ms Bonazzoli, Dr Bellone, Dr Buza, Dr Hui, Dr Lopez, Dr Perrone, Ms Manara, Dr Zammataro, Dr Altwerger, Dr Han, Dr Tymon-Rosario, Dr Menderes, Dr Ratner, Dr Silasi, Dr Huang, Dr Azodi, Dr Schwartz declare no competing interests.